{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009826","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.263806+00:00","generated_at":"2026-05-16T10:55:46.042634+00:00","sec_items":["1.01","2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nuvation Bio licenses taletrectinib to Eisai for up to €195M; Q4 IBTROZI rev $15.7M","bullets":["Exclusive license to Eisai for taletrectinib in EU, Canada, Australia, Middle East, India, others; upfront €50M, up to €145M milestones, royalties up to high-teens.","Preliminary Q4 IBTROZI net revenue $15.7M; total $24.7M since June 2025 launch; 432 new patient starts.","Preliminary cash $529.2M at Dec 31, 2025; received $25M milestone from Nippon Kayaku.","MAA for taletrectinib in Europe expected H1 2026; first €25M milestone upon EU approval.","Company continues enrollment of safusidenib phase 3 study in IDH1-mutant gliomas; full FY2025 results due March 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009826","json":"https://secwatch.observer/filing/0001193125-26-009826.json","markdown":"https://secwatch.observer/filing/0001193125-26-009826.md","text":"https://secwatch.observer/filing/0001193125-26-009826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/0001193125-26-009826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/d947742d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:55:46.042634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35d41ded5d1c9250837e68641e0b28269023cbac","claim":"Nuvation Bio Inc. entered into License Agreement with Eisai Co., Ltd. valued at €50 million (effective 2026-01-11).","evidence_excerpt":"On January 11, 2026, Nuvation Bio Inc. (the “Company”) entered into a License and Collaboration Agreement (the “License Agreement”) with Eisai Co., Ltd. (“Eisai”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/0001193125-26-009826-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Eisai Co., Ltd."},{"label":"Value","value":"€50 million"},{"label":"Effective","value":"2026-01-11"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}